| Identification | Back Directory | [Name]
ZD-1611 | [CAS]
186497-38-1 | [Synonyms]
ZD-1611
Benzenepropanoic acid, 4-[3-[[(3-methoxy-5-methyl-2-pyrazinyl)amino]sulfonyl]-2-pyridinyl]-α,α-dimethyl- | [Molecular Formula]
C22H24N4O5S | [MDL Number]
MFCD30533665 | [MOL File]
186497-38-1.mol | [Molecular Weight]
456.51 |
| Chemical Properties | Back Directory | [Boiling point ]
653.9±65.0 °C(Predicted) | [density ]
1.339±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [pka]
4.62±0.13(Predicted) |
| Hazard Information | Back Directory | [Uses]
ZD-1611 is a potent, orally active, selective ETA receptor antagonist, used for the research of ischemic stroke. | [in vivo]
ZD1611 (0.3 mg/kg, p.o.) has a duration of action of more than 7 h in rats. In the dog, ZD1611 is active for at least 6 h at dose of 0.6 mg/kg p.o[1]. ZD1611 (0.15 mg/kg/day) in combination with candesartan decreases the brain damage and improves the neurological scores in rats. However, ZD1611 or candesartan alone does not significantly decrease the brain damage or improve neurological scores[2]. | [IC 50]
ETA | [storage]
Store at -20°C | [References]
[1] Wilson C, et al. Pharmacological profile of ZD1611, a novel, orally active endothelin ETA receptor antagonist. J Pharmacol Exp Ther. 1999 Sep;290(3):1085-91. PMID:10454481
[2] Stenman E, et al. Cooperative effect of angiotensin AT(1) and endothelin ET(A) receptor antagonism limits the brain damage after ischemic stroke in rat. Eur J Pharmacol. 2007 Sep 10;570(1-3):142-8. Epub 2007 Jun 9. DOI:10.1016/j.ejphar.2007.05.049 |
|
| Company Name: |
MedChemExpress
|
| Tel: |
021-58955995 |
| Website: |
www.medchemexpress.com |
|